SG11202111907UA - Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof - Google Patents
Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereofInfo
- Publication number
- SG11202111907UA SG11202111907UA SG11202111907UA SG11202111907UA SG11202111907UA SG 11202111907U A SG11202111907U A SG 11202111907UA SG 11202111907U A SG11202111907U A SG 11202111907UA SG 11202111907U A SG11202111907U A SG 11202111907UA SG 11202111907U A SG11202111907U A SG 11202111907UA
- Authority
- SG
- Singapore
- Prior art keywords
- hydrate
- preparation
- application
- solid form
- method therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085207 | 2019-04-30 | ||
| PCT/CN2020/087687 WO2020221275A1 (en) | 2019-04-30 | 2020-04-29 | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111907UA true SG11202111907UA (en) | 2021-11-29 |
Family
ID=73029662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111907UA SG11202111907UA (en) | 2019-04-30 | 2020-04-29 | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220204475A1 (en) |
| EP (1) | EP3964505A4 (en) |
| JP (1) | JP2022530889A (en) |
| KR (1) | KR20220008284A (en) |
| CN (1) | CN113993858B (en) |
| AU (1) | AU2020265969A1 (en) |
| BR (1) | BR112021021721A2 (en) |
| CA (1) | CA3138234A1 (en) |
| MX (1) | MX2021013300A (en) |
| SG (1) | SG11202111907UA (en) |
| TW (2) | TWI806708B (en) |
| WO (1) | WO2020221275A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (en) * | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | P2X3 and/or P2X2/3 receptor antagonists, pharmaceutical compositions containing same and uses thereof |
| US20220177447A1 (en) * | 2019-04-30 | 2022-06-09 | Beijing Tide Pharmaceutical Co., Ltd. | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1930135B (en) * | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| BRPI0611375A2 (en) * | 2005-05-23 | 2010-08-31 | Novartis Ag | crystalline and other forms of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-yl] -1h-quinolin-2-one lactic acid salts |
| JP4850911B2 (en) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Diaminopyrimidines as P2X3 and P2X2 / 3 modulators |
| BR112018068399A2 (en) * | 2016-03-14 | 2019-01-15 | Afferent Pharmaceuticals Inc | pyrimidines and variants thereof and uses thereof |
| MA44489A (en) * | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | PYRIMIDINS AND VARIANTS THEREOF, AND THEIR USES |
| CN108778280B (en) * | 2016-11-07 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Polymorphism of GnRH receptor antagonist and preparation method thereof |
| PT3539545T (en) * | 2016-11-14 | 2021-09-06 | Jiangsu Hengrui Medicine Co | Crystalline form of gnrh receptor antagonist and preparation method therefor |
| JP2020502043A (en) * | 2016-12-22 | 2020-01-23 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | Solid forms of 4'-thio-2'-fluoronucleoside phosphamide compounds and methods of preparation therefor and uses thereof |
| JP6230743B1 (en) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | Crystals of heterocyclideneacetamide derivatives |
| JP7207634B2 (en) * | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | P2X3 and/or P2X2/3 receptor antagonists, pharmaceutical compositions containing same and uses thereof |
| US10457740B1 (en) * | 2018-01-29 | 2019-10-29 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using P2RX2 inhibitors |
| US20220177447A1 (en) * | 2019-04-30 | 2022-06-09 | Beijing Tide Pharmaceutical Co., Ltd. | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
-
2020
- 2020-04-29 CN CN202080032502.6A patent/CN113993858B/en active Active
- 2020-04-29 CA CA3138234A patent/CA3138234A1/en active Pending
- 2020-04-29 BR BR112021021721A patent/BR112021021721A2/en unknown
- 2020-04-29 WO PCT/CN2020/087687 patent/WO2020221275A1/en unknown
- 2020-04-29 SG SG11202111907UA patent/SG11202111907UA/en unknown
- 2020-04-29 US US17/607,449 patent/US20220204475A1/en active Pending
- 2020-04-29 KR KR1020217038591A patent/KR20220008284A/en unknown
- 2020-04-29 JP JP2021564188A patent/JP2022530889A/en active Pending
- 2020-04-29 MX MX2021013300A patent/MX2021013300A/en unknown
- 2020-04-29 EP EP20798323.0A patent/EP3964505A4/en active Pending
- 2020-04-29 AU AU2020265969A patent/AU2020265969A1/en active Pending
- 2020-04-30 TW TW111126506A patent/TWI806708B/en active
- 2020-04-30 TW TW109114697A patent/TWI773987B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220204475A1 (en) | 2022-06-30 |
| BR112021021721A2 (en) | 2021-12-28 |
| TWI806708B (en) | 2023-06-21 |
| MX2021013300A (en) | 2022-02-11 |
| AU2020265969A1 (en) | 2021-12-16 |
| TW202106675A (en) | 2021-02-16 |
| JP2022530889A (en) | 2022-07-04 |
| TWI773987B (en) | 2022-08-11 |
| CN113993858A (en) | 2022-01-28 |
| EP3964505A4 (en) | 2022-12-21 |
| EP3964505A1 (en) | 2022-03-09 |
| CN113993858B (en) | 2024-05-28 |
| CA3138234A1 (en) | 2020-11-05 |
| WO2020221275A1 (en) | 2020-11-05 |
| KR20220008284A (en) | 2022-01-20 |
| TW202241864A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106706TA (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| EP3572414A4 (en) | Compound used as bruton's tyrosine kinase inhibitor and preparation method and application thereof | |
| EP3594214A4 (en) | Polymorph of compound, preparation method therefor and use thereof | |
| ZA202102034B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| IL289395A (en) | Pyrazolone and pyrimidine compound, and preparation method and use therefor | |
| EP3640248A4 (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| EP3502105B8 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| EP3697791A4 (en) | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | |
| EP3793563A4 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3990445A4 (en) | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | |
| EP3842426A4 (en) | Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof | |
| EP4023221A4 (en) | Composition containing legoamodipine besylate hydrate and preparation method therefor | |
| SG11202111907UA (en) | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof | |
| EP3766880A4 (en) | Solid form of dihydropyrimidine compound and preparation method therefor and use thereof | |
| EP3461822A4 (en) | Crystalline form of chemical compound, and preparation method, composition, and application thereof | |
| EP3790552A4 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| EP3964500A4 (en) | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof | |
| IL282817A (en) | Novel compound, preparation method and application thereof | |
| EP3456712A4 (en) | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | |
| EP3902790C0 (en) | Improved method for the preparation of 4,6-dihydroxypyrimidine | |
| EP3872065A4 (en) | Sulfobiphenyl compound, preparation method therefor, and uses thereof | |
| EP3702356A4 (en) | Epoxy-oxetane compound, method for synthesizing same, and use of said compound | |
| PL3750893T3 (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
| SG11202008531RA (en) | Oxazino-quinazoline and Oxazino-quinoline Type Compound, Preparation Method and Uses Thereof |